As per the research report, the size of the Asia Pacific Preclinical CRO Agents Market was valued at USD 0.7 billion in 2020 and estimated to be growing at a CAGR of 8.59%, to reach USD 1.06 billion by 2025 during the forecast period 2020-2025.
A preclinical contract research organization is the guiding force for pharmaceutical companies advising how to take a drug from the research laboratories to the market. It requires various professionals including medical personnel, administrators, and marketing experts. Preclinical research is of prime importance and has various risks associated with it. This is the phase where there is a high chance that a product might fail and hence choosing a CRO becomes of prime importance.
An increasing number of life science of companies and outsourcing of various functions is driving the market growth. The rising number of R&D projects in the clinical phase segment is further propelling the market growth. Due to the failure of toxicology tests, the market is growing significantly. Supportive government policies regarding drug approval are expected to fuel the market growth during the forecast period.
This research report segmented and sub-segmented into the following categories:
Asia Pacific is expected to grow at a high CAGR.
The Top companies leading in the APAC Preclinical CRO Agents Market profiled in the report are Charles River Laboratories International, Inc.; Laboratory Corporation of America; Envigo, Eurofins Scientific; PRA Health Science, Inc.; Wuxi AppTec; Medpace, Inc.; Pharmaceutical Product Development, LLC.; and Paraxel International Corporation.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Service type
5.1.1 Introduction
5.1.2 Bioanalysis and DMPK studies
5.1.3 Toxicology testing
5.1.4 Other preclinical services
5.1.5 Y-o-Y Growth Analysis, By service type
5.1.6 Market Attractiveness Analysis, By service type
5.1.7 Market Share Analysis, By service type
5.2 End user
5.2.1 Introduction
5.2.2 Biopharmaceutical companies
5.2.3 Government and academic institutes
5.2.4 Medical device companies
5.2.5 Y-o-Y Growth Analysis, By end user
5.2.6 Market Attractiveness Analysis, By end user
5.2.7 Market Share Analysis, By end user
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By service type
6.1.3.3 By end user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By service type
6.1.4.3 By end user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By service type
6.1.5.3 By end user
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Charles River Laboratories International, Inc
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Laboratory Corporation of America
8.3 Envigo
8.4 Eurofins Scientific
8.5 PRA Health Science, Inc
8.6 Wuxi AppTec
8.7 Medpace, Inc
8.8 Pharmaceutical Product Development, LLC
8.9 Paraxel International Corporation
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
